US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
Supreme Court declines to hear challenge to Maryland ban on rifles known as assault weapons
WASHINGTON (AP) — The Supreme Court on Monday declined, for now, to hear a challenge to a Maryland l2024-05-22- An Ohio doctor who drew national attention when she told state legislators that COVID-19 vaccines ma2024-05-22
- An Ohio doctor who drew national attention when she told state legislators that COVID-19 vaccines ma2024-05-22
Rain cheque: The Singapore hotel that will pay YOU if there's a downpour
Clear skies and sunshine. That's what most people hope for when they go on holiday.This five-star ho2024-05-22Sports betting roundup: Xander Schauffele's final putt pays off for bettors
Xander Schauffele entered the PGA Championship with +1400 odds to win at BetMGM Sportsbook.That turn2024-05-22Boy Scouts of America changing name to more inclusive Scouting America after years of woes
IRVING, Texas (AP) — The Boy Scouts of America is changing its name for the first time in its 114-ye2024-05-22
atest comment